A New $286 Million Pot Buyout

$286 million. That's the total price tag to purchase Europe's #1 independent cannabis company. And one Nevada cannabis company could become a major buyout target. Go here for details on this $1.00 Pre-IPO. CuraLeaf (OTC: CURLF) is buying EMMAC Life Sciences (private) in a $286 million deal. The deal will give one for America's top 5 pot stocks a strong position in Europe. America's best cannabis stocks are rushing to buyout smaller players. Plus, they're looking to expand their geographic footprint across the country and around the globe. One undiscovered Nevada cannabis company is growing rapidly. And that's why it soon could become a buyout target. Right now, the company is raising $20 million from private investors. Go here to claim shares for just $1 – BEFORE the IPO. Ian Wyatt Take a 7 day break from these emails Unsubscribe from these types of emails Manage your email preferences Disclaimer & Important Information Wyatt Investment Research ("WIR") owns and publishes the website WyattResearch.com, other web sites, and, through its subscription services, various investment newsletters, trade alerts, and other investment-related educational materials. Those publications are informational in nature – WIR is not your financial adviser and does not provide any individualized investment advice to you. You should perform your own independent research on potential investments and consult with your financial adviser to determine whether an investment is appropriate given your financial needs, objectives, and risk appetite. This publication should not be construed as an offer to sell or the solicitation of an offer to buy any security. None of the case studies, examples, testimonials, investment return or income claims made on WIR's website or through its services is a guarantee of any income or investment results for you. WIR does not verify the income or investment results claims made in customer testimonials. Results for other customers may vary; for typical results, please see the Testimonial Support Page, linked below. Past success is not a predictor of future success. Trading in securities involves risks, including the risk of losing some or all of your investment. Hypothetical or modeled portfolio results do not represent the results of an actually invested portfolio and are not back-tested for accuracy under actual, historical market conditions. There can be tax consequences to trading; consult your tax adviser before entering into trades. For additional WIR disclosures and policies, please click the links below. Terms of Use | Privacy Policy Testimonial Support | Financial Disclaimer Trading Policies & WIR Compensation Unsubscribe | Delivery Preferences This is a communication from Wyatt Investment Research. You are subscribed with the following email address: its028@gmail.com If you believe this communication to be a mistake, please e-mail abuse@wyattresearchnewsletters.com with details regarding your situation, and we will be sure to promptly investigate your situation. Wyatt Investment Research 65 Railroad Street PO Box 790 Richmond, Vermont USA 05477